Long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals

Journal of Sexual Medicine

Volumn 4, Issue 5, 2007, Pages 1479-1484

  Jacobeit, Jens W ^a   Gooren, Louis J ^b   Schulte, Heinrich M ^a  

^a ENDOKRINOLOGIKUM HAMBURG   (Germany)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Hemoglobin; Lipids; Testosterone Undecanoate; Transgender Female

Indexed keywords

CHOLESTEROL; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN; LONG ACTING DRUG; LOW DENSITY LIPOPROTEIN; TESTOSTERONE; TESTOSTERONE UNDECANOATE;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL OBSERVATION; CONTROLLED STUDY; FEMALE; FEMALE TO MALE TRANSSEXUAL; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGONADISM; LIPOPROTEIN BLOOD LEVEL; POLYCYTHEMIA; PRIORITY JOURNAL; REPEATED DRUG DOSE; UNSPECIFIED SIDE EFFECT; VIRILIZATION;

EID: 34548301929     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2007.00556.x     Document Type: Article

References (21)

1. Levy A, Crown A, Reid R. Endocrine intervention for transsexuals. Clin Endocrinol (Oxf) 2003; 59: 409-18.
2. Moore E, Wisniewski A, Dobs A. Endocrine treatment of transsexual people: A review of treatment regimens, outcomes, and adverse effects. J Clin Endocrinol Metab 2003; 88: 3467-73.
3. Gooren L. Hormone treatment of the adult transsexual patient. Horm Res 2005; 64 (2 suppl): 31-6.
4. Sohn M, Bosinski HAG. Gender identity disorders: Diagnostic and surgical aspects. J Sex Med 2007 (in press).
5. Cohen-Kettenis PT, Gooren LJ. Transsexualism: A review of etiology, diagnosis and treatment. J Psychosom Res 1999; 46: 315-33.
6. Gooren L. The endocrinology of transsexualism: A review and commentary. Psychoneuroendocrinology 1990; 15: 3-14.
7. Spinder T, Spijkstra JJ, van den Tweel JG, Burger CW, van Kessel H, Hompes PG, Gooren LJ. The effects of long term testosterone administration on pulsatile luteinizing hormone secretion and on ovarian histology in eugonadal female to male transsexual subjects. J Clin Endocrinol Metab 1989; 69: 151-7.
8. Elbers JM, Giltay EJ, Teerlink T, Scheffer PG, Asscheman H, Seidell JC, Gooren LJ. Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects. Clin Endocrinol (Oxf) 2003; 58: 562-71.
9. Giltay EJ, Toorians AW, Sarabdjitsingh AR, de Vries NA, Gooren LJ. Established risk factors for coronary heart disease are unrelated to androgen-induced baldness in female-to-male transsexuals. J Endocrinol 2004; 180: 107-12.
10. Giltay EJ, Gooren LJ. Effects of sex steroid deprivation/administration on hair growth and skin sebum production in transsexual males and females. J Clin Endocrinol Metab 2000; 85: 2913-21.
11. von Eckardstein S, Nieschlag E. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: A phase II study. J Androl 2002; 23: 419-25.
12. Schubert M, Minnemann T, Hubler D, Rouskova D, Christoph A, Oettel M, Ernst M, Mellinger U, Krone W, Jockenhovel F. Intramuscular testosterone undecanoate: Pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab 2004; 89: 5429-34.
13. Harle L, Basaria S, Dobs AS. Nebido: A long-acting injectable testosterone for the treatment of male hypogonadism. Expert Opin Pharmacother 2005; 6: 1751-9.
14. van Kesteren PJ, Gooren LJ, Megens JA. An epidemiological and demographic study of transsexuals in the Netherlands. Arch Sex Behav 1996; 25: 589-600.
15. Spinder T, Spijkstra JJ, Gooren LJ, Hompes PG, van Kessel H. Effects of long-term testosterone administration on gonadotropin secretion in agonadal female to male transsexuals compared with hypogonadal and normal women. J Clin Endocrinol Metab 1989; 68: 200-7.
16. Toorians AW, Kelleher S, Gooren LJ, Jimenez M, Handelsman DJ. Estimating the contribution of the prostate to blood dihydrotestosterone. J Clin Endocrinol Metab 2003; 88: 5207-11.
17. Bunck MC, Toorians AW, Lips P, Gooren LJ. The effects of the aromatase inhibitor anastrozole on bone metabolism and cardiovascular risk indices in ovariectomized, androgen-treated female-to-male transsexuals. Eur J Endocrinol 2006; 154: 569-75.
18. Drinka PJ, Jochen AL, Cuisinier M, Bloom R, Rudman I, Rudman D. Polycythemia as a complication of testosterone replacement therapy in nursing home men with low testosterone levels. J Am Geriatr Soc 1995; 43: 899-901.
19. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005; 26: 833-76.
20. Jockenhovel F, Vogel E, Reinhardt W, Reinwein D. Effects of various modes of androgen substitution therapy on erythropoiesis. Eur J Med Res 1997; 2: 293-8.
21. Whitsel EA, Boyko EJ, Matsumoto AM, Anawalt BD, Siscovick DS. Intramuscular testosterone esters and plasma lipids in hypogonadal men: A meta-analysis. Am J Med 2001; 111: 261-9.